Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Growth factor networks and oestrogen receptor (ER) signalling are key regulators of breast cancer growth.
• Tumour response to endocrine therapy is influenced by both ER and growth factor signalling pathways.
• Understanding these interactions is crucial for overcoming endocrine resistance.

Purpose of the Study:

• To examine the modulation of growth factor networks during endocrine therapy response.
• To present evidence on the role of epidermal growth factor receptor (EGFR) signalling in endocrine-resistant breast cancer.
• To highlight the potential of EGFR-selective tyrosine kinase inhibitors in treating endocrine resistance.

Main Methods:

• In vitro studies investigating growth factor network modulation.
• Analysis of clinical data to assess tumour responses to endocrine therapy.
• Evaluation of EGFR signalling in ER-dependent and -independent breast cancer models.

Main Results:

• EGFR signalling, whether ER-dependent or -independent, is critical for the growth of endocrine-resistant breast cancer cells.
• Growth factor networks are significantly modulated during endocrine therapy.
• ZD 1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor, shows potential in preclinical models.

Conclusions:

• EGFR signalling plays a critical role in endocrine-resistant breast cancer.
• Targeting EGFR with tyrosine kinase inhibitors like ZD 1839 offers a promising strategy for treating endocrine-resistant breast cancer.
• This approach may also hold potential for preventing endocrine resistance.